Notice to Investors Regarding 2011 and 2015 Guidance
THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire via COMTEX/ --
Today, Amgen (NASDAQ: AMGN) issued the following notice to investors:
Amgen reaffirms its guidance for 2011 and 2015.
This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of June 24, 2011 and expressly disclaims any duty to update information contained in this news release.
Contact: Amgen, Thousand Oaks
Arvind Sood: (805) 447-1060 (investors)